LRRC15 Targeting in Soft-Tissue Sarcomas: Biological and Clinical Implications

First-in-human phase 1 study of ABBV-085, an antibody-drug conjugate (ADC) targeting LRRC15, in sarcomas and other advanced solid tumors.

(2019) George D. Demetri et al.   JOURNAL OF CLINICAL ONCOLOGY

LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody–Drug Conjugates

(2018) James W. Purcell et al.   CANCER RESEARCH

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

(2018) Maud Toulmonde et al.   JAMA Oncology

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

(2017) Hussein A Tawbi et al.   LANCET ONCOLOGY

Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates

(2017) Fu Li et al.   MOLECULAR CANCER THERAPEUTICS

Myxofibrosarcoma primary cultures: molecular and pharmacological profile

(2017) Alessandro De Vita et al.   Therapeutic Advances in Medical Oncology

Collagen type V promotes the malignant phenotype of pancreatic ductal adenocarcinoma

(2015) Sonja Berchtold et al.   CANCER LETTERS

The Pancreas Cancer Microenvironment

(2012) C. Feig et al.   CLINICAL CANCER RESEARCH

Trends in survival for patients with metastatic soft-tissue sarcoma

(2010) Antoine Italiano et al.   CANCER

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE